KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Amneal Pharmaceuticals (AMRX) Revenue: 2016-2024

Historic Revenue for Amneal Pharmaceuticals (AMRX) over the last 9 years, with Dec 2024 value amounting to $2.8 billion.

  • Amneal Pharmaceuticals' Revenue rose 11.68% to $784.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.9 billion, marking a year-over-year increase of 9.50%. This contributed to the annual value of $2.8 billion for FY2024, which is 16.73% up from last year.
  • Amneal Pharmaceuticals' Revenue amounted to $2.8 billion in FY2024, which was up 16.73% from $2.4 billion recorded in FY2023.
  • In the past 5 years, Amneal Pharmaceuticals' Revenue ranged from a high of $2.8 billion in FY2024 and a low of $2.0 billion during FY2020.
  • In the last 3 years, Amneal Pharmaceuticals' Revenue had a median value of $2.4 billion in 2023 and averaged $2.5 billion.
  • Data for Amneal Pharmaceuticals' Revenue shows a peak YoY increased of 22.51% (in 2020) over the last 5 years.
  • Amneal Pharmaceuticals' Revenue (Yearly) stood at $2.0 billion in 2020, then rose by 5.08% to $2.1 billion in 2021, then increased by 5.67% to $2.2 billion in 2022, then grew by 8.20% to $2.4 billion in 2023, then increased by 16.73% to $2.8 billion in 2024.